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1. Introduction
Maternal behavior in rats is a complex behavior that shares many 
features with human mothering behavior (Fleming and Corter, 
1988). It is naturally expressed for the first time with the birth of 
the first litter. Within hours of parturition, the mother rat recon-
structs the nest, retrieves the displaced pups, gathers them to-
gether in the nest site and adopts a nursing posture over the pups 
to permit suckling (Dollinger et al., 1980; Rosenblatt and Leh-
rman, 1963). The mother rat (dam) continues to exhibit maternal 
behavior (pup licking, pup retrieval, nest building and nursing) 
over the subsequent 3-week period, although as the pups mature, 
the intensity and quality of her behavior changes (Galef, 1981; 
Rosenblatt and Lehrman, 1963).
In recent years, we have used the rat maternal behavior as an 
ecologically relevant model to investigate the behavioral mech-
anisms of action of antipsychotic drugs and attempted to cap-
ture the possible side effects of antipsychotic medications on 
human parental behaviors. We and others have shown that clin-
ically comparable doses of haloperidol (HAL), clozapine (CLZ), 
risperidone and quetiapine (~ 50%–70% dopamine D2 occu-
pancy) disrupt active components of rat maternal behavior, such 
as pup retrieval, pup licking and nest building (Li et al., 2004; 
Stern and Taylor, 1991; Stern and Keer, 1999; Zhao and Li, 2009). 
HAL causes a prolonged disruption (up to 6 h), whereas CLZ and 
other atypical antipsychotics induce an early onset but transient 
disruption (less than 6 h). Novel antipsychotics such as amisul-
pride and aripiprazole also exhibit a certain degree of inhibition 
on active maternal responses in a dose-dependent fashion (Li et 
al., 2005a). Chronic treatment with HAL or olanzapine via mini-
pumps or repeated daily injections significantly inhibits rat ac-
tive maternal responses as well (Li et al., 2005b). It seems that 
antipsychotic-induced inhibition on pup retrieval, pup licking 
and nest building may be an inherent feature of all currently 
available antipsychotics (Li et al., 2004, 2005a; Silva et al., 2001; 
Stern and Taylor, 1991; Stern and Keer, 1999; Zhao and Li, 2009). 
Our recent work further identifies that sedation and suppres-
sion of maternal motivation are two important behavioral mech-
anisms underlying the disruptive effects of antipsychotic treat-
ment on maternal behavior (Zhao and Li, 2009).
The present study investigated the neurochemical basis of 
antipsychotic-induced disruptive effects on rat maternal be-
havior. For typical antipsychotics, it is generally assumed that 
they disrupt maternal behavior by blocking dopamine D2 recep-
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tors because they are primarily dopamine D2 antagonists (Dra-
gunow et al., 1990; Seeman et al., 1976), and because apomor-
phine, a dopamine receptor agonist, can reverse the inhibitory 
effects of haloperidol (Giordano et al., 1990). However, solid ev-
idence demonstrating that typical antipsychotics do act through 
this specific D2 mechanism is still lacking. For atypical antipsy-
chotics (e.g., clozapine, olanzapine), because they generally have 
multiple-receptor binding profiles (Meltzer, 1989; Miyamoto et 
al., 2005), it is hard to pinpoint their exact neurochemical mech-
anisms. Most atypical antipsychotics possess a much more po-
tent antagonism on the 5-HT2 receptor in addition to relatively 
weak antagonism on D2 receptor (Meltzer et al., 2003). It is thus 
possible that the disruptive effects of atypical antipsychotics on 
maternal behavior could be attributed to their action on D2 re-
ceptor alone (Kapur and Seeman, 2001) or to its dual action on 
both 5-HT2 and D2 receptors (Meltzer et al., 1989a, 1989b) or on 
other receptors.
In the present study, we administered quinpirole, a selective 
D2/D3 dopaminergic receptor agonist or 2,5-dimethoxy-4-iodo-
amphetamine (DOI), a selective 5-HT2A/2C serotonergic receptor 
agonist together with HAL (0.2 mg/kg) or CLZ (10.0 mg/kg) to 
postpartum rats. We examined which of these two agonists was 
able to reverse the disruptive effects induced by HAL or CLZ. We 
hypothesized that quinpirole, but not DOI, would be able to re-
verse the HAL-induced disruption on maternal behavior and 
may also be effective in alleviating the CLZ-induced disruption 
to some extent. We had no prior conviction regarding the effect 
of DOI due to lack of sufficient evidence in the literature on the 
role of serotonin in maternal behavior (Numan and Insel, 2003).
2. Materials and methods
2.1. Subjects
Animals were naive pregnant female Sprague–Dawley rats (9–
12 weeks old at the start of pregnancy) purchased from Charles 
River Inc. (Portage, MI). Upon arrival to our animal facility, 
the rats were between gestational days 13–15. Each subject was 
housed individually in 48.3 cm × 26.7 cm × 20.3 cm transparent 
polycarbonate cage lined with aspen shavings in a colony on a 
12-h light/dark cycle (lights on at 6:30 AM). All behavioral tests 
were performed in the light phase between 9:00 AM and 4:00 
PM. The colony was maintained under standard vivarium condi-
tions with an ambient temperature of 23 °C, relative humidity of 
55–60%. Standard laboratory rat chow and water were available 
adlibitum. All animal procedures were approved by the Univer-
sity of Nebraska Institutional Animal Care and Use Committee.
2.2. Drugs and choices of doses
HAL (5.0 mg/ml ampoules, Sicor Pharmaceuticals, Inc, Irvine, 
CA) was diluted with sterile water. CLZ (a gift from NIMH drug 
supply program) was dissolved in 1.0% glacial acetic acid in dis-
tilled water. Quinpirole (QUI) and DOI (RBI-Sigma, Natick, 
MA) were dissolved in 0.9% saline. HAL (0.2 mg/kg), CLZ 
(10.0 mg/kg), QUI (0.5 or 1.0 mg/kg), DOI (1.0 or 2.5 mg/kg) and 
vehicle (water or saline) were all administered subcutaneously 
in a volume of 1.0 ml/kg body weight. Choices of drug doses for 
HAL and CLZ were based on our previous studies showing that, 
at these doses, HAL and CLZ effectively disrupt active maternal 
behaviors in rats (Li et al., 2004; Zhao and Li, 2009). The doses 
of QUI were chosen based on our preliminary study showing 
that 1.0 mg/kg of QUI improved the HAL’s disruption on pup re-
trieval. DOI doses were chosen on the basis of reports showing 
that DOI at these doses potentiates the effects of amphetamine 
on dopamine release in the striatum, medial prefrontal cortex 
and nucleus accumbens (Ichikawa and Meltzer, 1995; Kuroki et 
al., 2003) and blocks the CLZ-induced dopamine release in the 
medial prefrontal cortex (Ichikawa et al., 2001).
2.3. Basic experimental procedure
Starting 2 or 3 days prior to the first possible expected parturi-
tion date, the subjects were monitored every morning for signs 
of parturition. Once the dam was found with pups in the morn-
ing (that day was designated as Day 1 postpartum), the mother 
was transferred into a clean cage with wood shavings for bed-
ding. Two shredded paper towels were also provided for nesting 
material. The litter was culled to 8 pups (4 males and 4 females 
with the most visible milk bands). Maternal behavior tests were 
conducted on one day between Days 6 and 8 postpartum.
2.4. Maternal behavior test
The basic procedure was similar to what has been described in 
Zhao and Li (2009). Using a laptop computer with an event re-
cording program (JWatcher, http://www.jwatcher.ucla.edu/), we 
recorded various components of maternal behavior in an 8-min 
testing session at different time points before and after drug ad-
ministration. Each test started by removing the 8 pups from the 
dam and destroying the nest. Ten seconds later, the pups were 
returned to the corner of the cage diagonal to the nest site or 
dam sleeping corner. When the subject picked up a pup in her 
mouth and carried it back to the nest site, it was referred to as 
a successful pup retrieval. The total number of pups retrieved 
was recorded. Approach latency was defined as the time taken 
for mother rats to approach and sniff the pups from the reunion. 
First and last pup retrieval latency was defined as the time 
elapsed from the first pup approach to the retrieval of the first 
and eighth pup into the nest, respectively. A score of 480 s was 
assigned to non-responders who did not approach or retrieve 
the testing pups at all. The occurrence of other behaviors was 
also recorded, including pup nursing behavior (a rat position-
ing herself over the pups with legs splayed to accommodate the 
pups, including hover, high and low crouching over postures), 
pup licking (a female rat placing its tongue on the anogeni-
tal area and the rest of a pup’s body), nest building (a rat pick-
ing up nesting material in her mouth and transporting it back 
to the nest site or pushing the material with her forepaws toward 
the nest site). At the conclusion of the test, any unretrieved pups 
were returned to the nest site.
2.4.1. Experiment 1. Effects of pretreatment with quinpirole or 
DOI on haloperidol-induced maternal behavior deficits in rats
Forty-four postpartum rats were randomly assigned to one of the 
following six groups: VEH+VEH (n = 4, sterile water or saline), 
VEH+HAL (n = 8), QUI-0.5+HAL (n = 8), QUI-1.0+HAL (n = 8), 
DOI-1.0+HAL (n = 8), and DOI-2.5+HAL (n = 8). On the drug 
test day (1 day on either Postpartum Day 6, 7, or 8), all subjects 
were tested 5 times at different time points before and after drug 
administrations, with the first maternal behavior test starting at 
30 min prior to the HAL or vehicle injection (i.e., baseline) and 
the other tests occurring at 30, 60, 120 and 240 min after HAL 
or vehicle injection. QUI, DOI or vehicle was injected s.c. twice 
with the first injection at 10 min before and the second at 50 min 
after the HAL or vehicle injection. We adopted such an injec-
tion strategy because our preliminary data showed that injection 
of QUI at 10 min prior to the administration of HAL could opti-
mally reverse its disruption on pup retrieval. Also, agonists were 
injected twice separately on the basis of their relatively short du-
ration of action and rapid peak plasma concentrations (Deutch 
and Duman, 1996; Whitaker and Lindstrom, 1987).
2.4.2. Experiment 2. Effects of pretreatment with quinpirole or 
DOI on clozapine-induced maternal behavior deficits in rats
The basic procedure was identical to that of Experiment 1 with 
the exception that CLZ was tested in this experiment instead 
of haloperidol. Forty-four postpartum rats were randomly as-
signed to one of the following six groups and their maternal be-
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haviors were tested: VEH+VEH (n = 4, sterile water or saline), 
VEH+CLZ (n = 8), QUI-0.5+CLZ (n = 8), QUI-1.0+CLZ (n = 8), 
DOI-1.0+CLZ (n = 8), and DOI-2.5+CLZ (n = 8).
2.5. Data analysis
With the exception of latency data, various measurements of 
maternal behavior were expressed as mean ± SEM. To increase 
statistical power, we combined the two vehicle control groups 
from Experiments 1 and 2 into a single group since they did not 
differ significantly on any measure (Independent-Samples T test 
or Mann–Whitney U test, all ps > 0.10). Data were analyzed us-
ing a factorial repeated measures analysis of variance (ANOVA) 
with the between-subjects factor being the treatment groups 
(e.g. saline, HAL) and the within-subjects factor being test time 
points (baseline, 30, 60, 120 and 240 min post-injection). Group 
differences at different time points were further analyzed using 
simple main effect test (one-way ANOVA) followed by Turkey’s 
HSD post hoc tests where appropriate.
For the latency data, because they were not normally distrib-
uted (e.g. the cut-off time assigned 480 s for the latency data), 
these data were expressed as median ± interquartile range. Non-
parametric Kruskal–Wallis test was used for analyzing the differ-
ences among the treatment groups. Once the overall significant 
effects were determined, two-group comparisons were per-
formed using Mann–Whitney U test. A conventional two-tailed 
level of significance at the 0.05 level was required.
3. Results
3.1. Experiment 1. Effects of pretreatment with QUI or DOI 
on haloperidol-induced maternal behavior deficits
3.1.1. Haloperidol treatment disrupted various components of ma-
ternal behavior
Consistent with our previous findings (Li et al., 2004; Zhao and 
Li, 2009), a single injection of HAL significantly disrupted vari-
ous active components of maternal behavior (pup retrieval, pup 
licking, nest building, but not pup nursing). Rats treated with 
HAL took a much longer time to initiate contact with pups and 
retrieve their pups into the nest sites (Table 1) and retrieved 
fewer pups at the 30, 60, 120 and 240 min test points (Figure 
1 and Figure 2A) (0.001 < all ps < 0.05) compared to the vehi-
cle-treated rats. They also spent less time licking their pups at 
the 30, 60 and 120 min test points and rebuilding the nest at the 
30, 60, 120 and 240 min test points ( Figure 1 & Figure 2 B,C) 
(0.001 < all ps < 0.05). However, HAL treatment had no signifi-
cant effect on nursing activity ( Figure 1 & Figure 2D).
3.1.2. QUI pretreatment dose-dependently improved the haloperi-
dol-induced maternal behavior deficits
As can be seen in Table 1 and Figure 1A–C, both doses of QUI im-
proved the HAL-induced deficits in pup approach, pup retrieval, 
pup licking and nest building, as described below.
3.1.2.1. Latency to approach and retrieve pups.  QUI short-
ened the HAL-induced increase in pup approach latency and 
the first and last pup retrieval latencies (Table 1). Both 0.5 and 
1.0 mg/kg doses of QUI were effective in facilitating the HAL-
treated dams to initiate contact with their pups and completely 
restored such behavior to the normal level (e.g., VEH+VEH 
group) across the testing period. For the pup retrieval latency, it 
appeared that both doses of QUI shortened the time the HAL-
treated rats took to retrieve their first and last pups to the nest 
site and reinstated the first pup retrieval to the normal level at 
the 30, 120 and 240 min test points post-injection.
3.1.2.2. Number of pups retrieved.  Both 0.5 and 1.0 mg/kg of 
QUI increased the number of pups retrieved in the HAL-treated 
rats and restored it to the normal level at certain time points of 
testing. Repeated measures ANOVA revealed that there was a sig-
nificant interaction between the treatment groups and time points 
[F (20, 168) = 5.97, p < 0.001], a significant main effect of treatment 
groups [F (5, 42) =26.30, p < 0.001], and a significant effect of time 
points [F (4, 168) =35.22, p < 0.001]. One-way ANOVA and post hoc 
tests showed that the QUI-0.5+HAL group was significantly differ-
ent from the VEH+HAL group at the 30 and 120 min time points 
(Figure 1A, p < 0.001 for 30 min, p = 0.022 for 120 min), whereas 
the QUI-1.0+HAL group differed from the VEH+HAL group at the 
30, 120 and 240 min test points (Figure 1A, p < 0.001 for 30 and 
120 min, p = 0.014 for 240 min). Further analysis showed that the 
reversing effect of 0.5 mg/kg of QUI reached the control level at 
the 30 and 120 min test points while the 1.0 mg/kg of QUI restored 
the CLZ-induced disruption to the normal level at the 30, 120 and 
240 min test points when the two QUI+HAL groups were com-
pared with the VEH+VEH control group (Figure 1A, all ps > 0.10). It 
appears that the strongest reversal effect of QUI occurred 120 min 
after HAL administration (Figure 1A).
3.1.2.3. Pup licking.  QUI produced a reversing effect on HAL-
induced pup licking deficit. Repeated measures ANOVA revealed 
a main effect of treatment groups [F (5, 42) = 4.56, p = 0.002], a 
significant effect of test time points [F (4, 168) = 7.71, p < 0.001], 
but no significant interaction between the two factors. One-way 
ANOVA and post hoc tests showed that both QUI groups differed 
significantly from the VEH+HAL group at the 120 min test point 
(Figure 1B, p = 0.045 for QUI-0.5+HAL group, p = 0.042 for QUI-
1.0+HAL group). Further analysis showed that the reversing effect 
Table 1. Effects of pretreatment with quinpirole or DOI on pup approach latency and pup retrieval latency in postpartum female rats treated with hal-
operidol or vehicle.
Groups N Approach latency (s)    First pup retrieval latency (s)   Last pup retrieval latency (s)
  Baseline 30 min 60 min 120 min 240 min Baseline 30 min 60 min 120 min 240 min Baseline 30 min 60 min 120 min 240 min
VEH+VEH 8 2.1 1.2 1.5 1.5 1.9 2.8 2.0 2.6 2.1 1.9 38.3 22.6 23.9 21.7 24.0
  (2.0) (0.7) (1.2) (0.8) (4.6) (87.0) (0.9) (1.4) (0.7) (0.5) (104.0) (9.7) (7.7) (9.8) (14.4)
VEH+HAL 8 1.8 15.6a 87.5a 45.4a 23.2a 11.7 480.0a 480.0a 480.0a 245.6a 112.4 480.0a 480.0a 480.0a 480.0a
  (0.9) (106.9) (311.7) (224.6) (135.1) (100.8) (0.0) (0.0) (0.0) (476.1) (382.9) (0.0) (0.0) (0.0) (272.7)
QUI-0.5+HAL 8 1.4 2.2b 3.4b 2.6b 8.8b 47.4 4.0b 480.0a 3.3b 3.3b 141.0 75.9a,b 480.0a 285.4a 74.0a,b
  (0.8) (15.1) (26.9) (5.6) (41.6) (89.6) (35.7) (357.8) (358.2) (358.4) (289.1) (55.9) (241.2) (443.6) (352.6)
QUI-1.0+HAL 8 2.8 2.8b 12.5b 7.7b 5.6b 30.7 4.3b 247.1a 3.1b 2.4b 152.3 105.7a,b 480.0a 145.9a,b 67.1a,b
  (4.1) (7.4) (78.1) (24.5) (14.2) (84.1) (12.0) (474.9) (2.0) (0.7) (260.0) (417.8) (284.9) (104.0) (45.5)
DOI-1.0+HAL 8 1.3 13.1a 115.7a 43.6a 30.6a 2.8 293.6a 480.0a 480.0a 65.2a 179.7 480.0a 480.0a 480.0a 480.0a
  (0.7) (29.5) (122.6) (52.2) (361.4) (189.40 (441.1) (0.0) (0.0) (476.8) (450.6) (0.0) (0.0) (0.0) (356.1)
DOI-2.5+HAL 8 2.0 49.3a 480.0a,b 278.6a 81.9a 3.1 480.0a 480.0a 480.0a 480.0a 69.6 480.0a 480.0a 480.0a 480.0a
  (5.9) (107.8) (169.4) (446.2) (216.1) (15.3) (0.0) (0.0) (0.0) (0.0) (59.2) (0.0) (0.0) (0.0) (0.0)
Data are represented as median ± interquartile range.
a. p < 0.05 relative to the VEH+VEH group; b. p < 0.05 relative to the VEH+HAL group
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reached the normal level when the two QUI+HAL groups were 
compared to the VEH+VEH control group (Figure 1B, p = 0.85 for 
QUI-0.5+HAL group, p = 0.95 for QUI-1.0+HAL group).
3.1.2.4. Nest building.   Similar to the effect on pup retrieval and 
pup licking, both doses of QUI significantly improved the HAL-
induced disruption of nest building activity. Repeated measures 
ANOVA revealed a significant interaction between the two factors 
[F (20, 168) = 6.18, p < 0.001], a significant main effect of treatment 
groups [F (5, 42) = 17.52, p < 0.001], and a significant effect of test-
ing time [F (4, 168) = 35.95, p < 0.001]. One-way ANOVA and post 
hoc tests showed that the QUI-0.5+HAL group was significantly 
different from the VEH+HAL group at the 120 and 240 min test 
points (both ps = 0.021), whereas the QUI-1.0+HAL group differed 
significantly from the VEH+HAL group at the 30, 120 and 240 min 
test points post-injection (Figure 1C, all ps < 0.001). In particular, 
although both doses of QUI reversed the disruptive effect of HAL 
at the 120 min test point, only 1.0 mg/kg of QUI was capable of 
improving it to the normal level when compared to the VEH+VEH 
group (Figure 1C, p = 0.34).
Figure 1. The time course of effects of the dopamine D2/D3 receptor ag-
onist quinpirole on various HAL-induced maternal behavior deficits in 
postpartum female rats. Pup retrieval (A), pup licking (B), nest building 
(C) and pup nursing (D) were tested at baseline, 30, 60, 120 and 240 min 
after injection of HAL or vehicle. HAL disrupted all the active mater-
nal behaviors tested (A–C), but had no significant effect on pup nurs-
ing (D). Both 0.5 and 1.0 mg/kg of quinpirole improved the maternal be-
havior deficits induced by HAL in a dose-dependent fashion (A–C). Data 
were represented as mean + SEM. * p < 0.05 versus VEH+VEH control; # 
p < 0.05 versus VEH+HAL group.
Figure 2. The time course of effects of the 5-HT2A/2C receptor agonist 
DOI on various HAL-induced maternal behavior deficits in postpar-
tum female rats. Pup retrieval (A), pup licking (B), nest building (C) 
and pup nursing (D) were tested at baseline, 30, 60, 120 and 240 min af-
ter injection of HAL or vehicle. HAL disrupted all the active maternal 
behaviors tested (A–C), but had no significant effect on pup nursing 
(D). Neither 1.0 nor 2.5 mg/kg of DOI rescued the HAL-induced defi-
cits on active maternal behaviors (A–C), but 2.5 mg/kg of DOI further 
suppressed nursing activity in HAL-treated dams (D). Data were repre-
sented as mean + SEM. * p < 0.05 versus VEH+VEH control; # p < 0.05 
versus VEH+HAL group.
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3.1.2.5. Pup nursing.   As can be seen in Figure 1D, QUI pre-
treatment had no significant effect on pup nursing. Repeated 
measures ANOVA revealed a significant interaction between the 
two factors [F (20, 168) = 2.14, p = 0.005], a significant main ef-
fect of treatment groups [F (5, 42) = 4.66, p = 0.002], and a sig-
nificant effect of testing time [F (4, 168) = 10.53, p < 0.001]. Post 
hoc tests showed that both QUI groups were not significantly 
different from the VEH+HAL group (both ps > 0.10).
3.1.3. DOI pretreatment failed to improve the haloperidol-induced 
maternal behavior deficits
Both 1.0 and 2.5 mg/kg of DOI failed to improve the HAL-in-
duced disruption on pup approach and pup retrieval, as evi-
denced by no significant improvement in the approach latency 
nor in first and last pup retrieval latency (Table 1) when the 
two DOI+HAL groups were compared to the VEH+HAL group. 
Rather, 2.5 mg/kg of DOI further exacerbated the HAL-induced 
disruption on the approach latency at the 60 min test point (Ta-
ble 1, p = 0.005). Post hoc tests on the number of pups retrieved, 
pup licking and nest building revealed that there was no sig-
nificant difference between the two DOI+HAL groups and the 
VEH+HAL group. For pup nursing, one-way ANOVA and post 
hoc tests indicated that the DOI-2.5+HAL group showed an even 
more suppressed nursing duration at the 30 and 120 min test 
points compared to the VEH+HAL group (p = 0.048 for 30 min, 
p = 0.041 for 120 min) (Figure 2D). The DOI-1.0+HAL group did 
not differ significantly from the VEH+HAL group across the test-
ing period.
3.2. Experiment 2. Effects of pretreatment with QUI or DOI 
on clozapine-induced maternal behavior deficits
3.2.1. Clozapine treatment impaired various components of 
maternal behavior
Consistent with our previous findings (Li et al., 2004; Zhao and 
Li, 2009), the present study showed that a single injection of 
CLZ significantly disrupted various active components of mater-
nal behavior and maintained such a disruptive effect for about 
2 h. In comparison with the vehicle-treated ones, rats treated 
with CLZ took a much longer time to approach and retrieve their 
first pups into the nest sites (Table 2) at the 30, 60 and 120 min 
test points (0.001 < all ps < 0.01) and took longer to bring the last 
pups into the nest with less pups retrieved across the testing pe-
riod (Table 2, Figure 3 & Figure 4A) (0.001 < all ps < 0.05). They 
also spent less time on pup licking, nest building and pup nurs-
ing at the 30, 60 and 120 min test points ( Figure 3 and Figure 
4B,C,D) (all ps < 0.05).
3.2.2. QUI pretreatment failed to improve the clozapine-induced 
maternal behavior deficits
In contrast to its effects on HAL-induced maternal behavior def-
icits, both doses of QUI had little effect on the CLZ-induced dis-
ruptions of pup approach, pup retrieval latency (Table 2), the 
number of pups retrieved and nest building (Figure 3A,C). Con-
trarily, QUI further potentiated the disruptive effect on these be-
haviors (Table 2, Figure 3A,C). Repeated measures ANOVA on the 
number of pups retrieved and nest building revealed a significant 
interaction between the treatment groups and test time points 
[the number of pups retrieved:F (20, 168) = 9.56, p < 0.001; nest 
building: F (20, 168) =2.77, p < 0.001], a significant main effect of 
treatment groups [the number of pups retrieved: F (5, 42) = 20.41, 
p < 0.001; nest building: F (5, 42) =13.61, p < 0.001], and a signifi-
cant effect of test time points [the number of pups retrieved:F (4, 
168) = 61.43, p < 0.001; nest building: F (4, 168) =38.33, p < 0.001]. 
One-way ANOVA and post hoc tests showed that the QUI-
1.0+CLZ group differed significantly from the VEH+CLZ group in 
the number of pups retrieved and the duration of nest building 
at the 240 min test point (Figure 3A,C, p = 0.001 for the number 
of pups retrieved, p = 0.007 for the nest building), while the QUI-
0.5+CLZ group differed from the VEH+CLZ group in nest building 
at the 240 min test point (Figure 3C, p = 0.026). QUI pretreatment 
also did not improve the CLZ-induced deficits in pup licking and 
pup nursing activities (Figure 3B,D) at any test points. Repeated 
measures ANOVA on pup licking and pup nursing revealed a sig-
nificant interaction between the two factors [pup licking:F (20, 
168) = 1.68, p = 0.04; pup nursing: F (20, 168) = 2.05, p = 0.007], 
a significant main effect of treatment groups [pup licking: F (5, 
42) = 4.47, p = 0.002; pup nursing: F (5, 42) = 5.52, p = 0.001], and 
a significant effect of test time points [pup licking:F (4, 168) =8.02, 
p < 0.001; pup nursing: F (4, 168) = 6.72, p < 0.001]. Post hoc tests 
on pup licking and pup nursing revealed that there was no sig-
nificant difference between the two QUI+CLZ groups and the 
VEH+CLZ group.
3.2.3. DOI pretreatment dose-dependently reversed the clozapine-
induced maternal behavior deficits
As shown in Table 2 and Figure 4A,B, pretreatment of both doses 
of DOI (1.0 and 2.5 mg/kg) significantly improved the CLZ-in-
duced disruption on pup approach, pup retrieval, and pup lick-
ing. However, the reversing effect of DOI on CLZ-induced dis-
ruption of nest building and pup nursing was not apparent 
(Figure 4C,D).
3.2.3.1. Latency to approach and retrieve pups.  As shown in 
Table 2, both 1.0 and 2.5 mg/kg of DOI shortened the prolonged 
approach latency induced by CLZ when the two DOI+CLZ 
groups were compared to the VEH+CLZ group and restored it to 
the normal level compared to the VEH+VEH group at the 30, 60 
and 120 min test points (0.001 < all ps < 0.01). It also reduced the 
CLZ-induced deficits of the first pup retrieval and restored it to 
Table 2. Effects of pretreatment with quinpirole or DOI on pup approach latency and pup retrieval latency in postpartum female rats treated with clo-
zapine or vehicle.
Groups N Approach latency (s)    First pup retrieval latency (s)   Last pup retrieval latency (s)
  Baseline 30 min 60 min 120 min 240 min Baseline 30 min 60 min 120 min 240 min Baseline 30 min 60 min 120 min 240 min
VEH+VEH 8 2.1 1.2 1.5 1.5 1.9 2.8 2.0 2.6 2.1 1.9 38.3 22.6 23.9 21.7 24.0
  (2.0) (0.7) (1.2) (0.8) (4.6) (87.0) (0.9) (1.4) (0.7) (0.5) (104.0) (9.7) (7.7) (9.8) (14.4)
VEH+CLZ 8 1.8 68.5a 290.8a 21.8a 10.2 5.9 480.0a 480.0a 480.0a 13.0 40.8 480.0a 480.0a 480.0a 115.4a
  (1.7) (357.3) (474.6) (477.2) (43.7) (10.4) (357.1) (0.0) (346.9) (154.8) (130.8) (0.0) (0.0) (0.0) (420.6)
QUI-0.5+CLZ 8 8.7 177.2a 302.9a 268.2a 3.7 14.3 480.0a 480.0a 480.0a 480.0a,b 65.7 480.0a 480.0a 480.0a 480.0a
  (16.2) (473.2) (330.3) (432.7) (7.6) (20.6) (0.0) (0.0) (0.0) (339.1) (146.3) (0.0) (0.0) $(0.0) (0.0)
QUI-1.0+CLZ 8 5.3 159.9a 129.0a 319.3a 401.4a,b 10.4 480.0a 480.0a 480.0a 480.0a,b 143.4 480.0a 480.0a 480.0a 480.0a
  (9.1) (460.3) (240.4) (464.0) (442.5) (75.1) (0.0) (0.0) (0.0) (0.0) (408.2) (0.0) (0.0) (0.0) (0.0)
DOI-1.0+CLZ 8 2.2 6.9b 1.8b 1.7b 2.2 7.7 8.0a 2.8b 3.4 3.2 107.3 391.4a 58.3b 214.7b 44.8
  (1.1) (38.4) (24.5) (1.2) (5.3) (168.0) (363.1) (358.7) (441.4) (360.7) (442.8) (440.3) (453.3) (452.0) (456.8)
DOI-2.5+CLZ 8 1.6 1.8b 1.3b 1.3b 1.8 2.7 21.8a 2.5b 2.4b 2.2 37.13 480.0a 56.93b 45.13b 34.4b
  (2.6) (0.4) (7.2) (34.6) (4.9) (1.7) (371.5) (63.4) (34.8) (3.8) (32.0) (396.9) (372.2) (104.7) (54.7)
Data are represented as median ± interquartile range.
a. p < 0.05 relative to the VEH+VEH group; b. p < 0.05 relative to the VEH+CLZ group.
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the normal level at the 60 min test point (p = 0.035) at a dose 
of 1.0 mg/kg as well as at the 60 and 120 min test points (both 
ps < 0.01) at a dose of 2.5 mg/kg. For the last pup retrieval la-
tency, both doses of DOI completely rescued the disruption at 
the 60 and 120 min (0.001 < all ps < 0.01) test points. Further-
more, 2.5 mg/kg of DOI shortened the last pup retrieval latency 
at the 240 min test point (p = 0.001).
3.2.3.2. Number of pups retrieved.  Both doses of DOI in-
creased the number of pups retrieved in the CLZ-treated rats. 
One-way ANOVA and post hoc tests showed that there was a 
significant difference between the DOI-1.0+CLZ group and the 
VEH+CLZ group at the 60 and 120 min test points (p = 0.006 
for 60 min, p = 0.008 for 120 min), whereas the DOI-2.5+CLZ 
group differed significantly from the VEH+CLZ group even at 
Figure 3. The time course of effects of the dopamine D2/D3 receptor ag-
onist quinpirole on various CLZ-induced maternal behavior deficits in 
postpartum female rats. Pup retrieval (A), pup licking (B), nest building 
(C) and pup nursing (D) were tested at baseline, 30, 60, 120 and 240 min 
after injection of CLZ or vehicle. CLZ disrupted all maternal behaviors 
tested (A–D). Both doses of quinpirole (0.5 and 1.0 mg/kg) failed to im-
prove the maternal behavior deficits induced by CLZ (A–D), but rather 
worsened pup retrieval (A) and nest building (C) deficits. Data were rep-
resented as mean + SEM. * p < 0.05 versus VEH+VEH control; # p < 0.05 
versus VEH+CLZ group.
Figure 4. The time course of effects of the 5-HT2A/2C receptor agonist 
DOI on various CLZ-induced maternal behavior deficits in postpartum 
female rats. Pup retrieval (A), pup licking (B), nest building (C) and pup 
nursing (D) were tested at baseline, 30, 60, 120 and 240 min after injec-
tion of CLZ or vehicle. CLZ disrupted all maternal behaviors tested (A–
D). Both doses of DOI (1.0 and 2.5 mg/kg) significantly improved the 
pup retrieval and pup licking deficits induced by CLZ (A, B). However, 
DOI did not improve the CLZ-induced disruption on nest building and 
pup nursing (C, D). Data were represented as mean + SEM. * p < 0.05 
versus VEH+VEH control; # p < 0.05 versus VEH+CLZ group.
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the 240 min test point (Figure 4A, 0.001 < all ps < 0.05). Fur-
ther analysis showed that the reversing effect of 1.0 mg/kg of 
DOI reached the normal level at the 60 and 120 min test points 
while the 2.5 mg/kg of DOI restored the CLZ-induced disruption 
to the normal level at 60, 120 and 240 min test points (Figure 4A, 
all ps > 0.05). It appears that the strongest reversal effect of DOI 
occurred 120 min after CLZ administration (Figure 4A).
3.2.3.3. Pup licking.  Both doses of DOI alleviated the CLZ-in-
duced disruption on pup licking. One-way ANOVA and post hoc 
tests showed that there was a significant difference between the 
DOI-1.0+CLZ group and the VEH+CLZ group at the 120 min test 
point (p = 0.049), while the DOI-2.5+CLZ group differed sig-
nificantly from the VEH+CLZ group at the 60 and 120 min test 
points (Figure 4B, p = 0.034 for 60 min, p = 0.015 for 60 min). 
Further analysis showed that only 2.5 mg/kg of DOI restored 
this behavior to the normal level at the 60 and 120 min test 
points when the two DOI+CLZ groups were compared with the 
VEH+VEH control group (Figure 4B, both ps > 0.05).
3.2.3.4. Nest building and pup nursing.  Compared to the re-
versing effects on pup retrieval and pup licking, DOI at the cur-
rently tested doses appeared to be ineffective in reversing the 
CLZ-induced deficits on nest building and pup nursing. Post hoc 
tests on nest building and pup nursing revealed that there was 
no significant difference between the two DOI+CLZ groups and 
the VEH+CLZ group (Figure 4C,D, all ps > 0.05).
4. Discussion
The present study demonstrates an interesting double dissocia-
tion between dopamine and serotonin receptor mechanisms in 
the mediation of HAL- and CLZ-induced maternal behavior def-
icits in postpartum rats. Acute treatment of HAL and CLZ dis-
rupted various components of rat maternal behavior. Pretreat-
ment of QUI, a selective D2/D3 dopaminergic receptor agonist, 
but not DOI, a selective 5-HT2A/2C serotonergic receptor agonist, 
dose-dependently improved HAL-induced disruption of pup ap-
proach, pup retrieval, pup licking and nest building, whereas 
pretreatment of DOI, but not QUI, dose-dependently improved 
CLZ-induced disruption of pup approach, pup retrieval and pup 
licking. These data strongly suggest that the HAL-induced ma-
ternal deficits are primarily mediated by its blockade of D2 dopa-
mine receptors, whereas the CLZ-induced maternal deficits are 
primarily mediated by the blockade of 5-HT2A/2C receptors.
The dopamine systems have been well documented to play 
an important role in the regulation of maternal behavior. For ex-
ample, systemic (e.g., haloperidol, a D2 antagonist) or microin-
fusion of dopamine receptor antagonists such as SCH-23390 (a 
D1 antagonist), pimozide (a D2 antagonist) and cis-flupenthixol 
(a mixed D1/D2 antagonist) into the specific brain regions impli-
cated in maternal behavior (e.g., medial preoptic area, nucleus 
accumbens) disrupts various active maternal behaviors (Byrnes 
et al., 2002; Giordano et al., 1990; Keer and Stern, 1999; Li et al., 
2004; Miller and Lonstein, 2005; Numan et al., 2005; Numan and 
Stolzenberg, 2009; Silva et al., 2001, 2003; Stern and Taylor, 1991). 
6-OHDA lesion of the ventral striatum and ventral tegmental 
area disrupts pup retrieval (Hansen, 1994; Hansen et al., 1991a, 
1991b). Additionally, mother–pup separation, which putatively 
enhances maternal motivation (Hansen, 1994), stimulates do-
pamine release in the ventral striatum of maternal rats (Hansen 
et al., 1993). Because HAL is primarily a D2 receptor antagonist, 
we hypothesized that it disrupts maternal behavior by block-
ing D2 dopamine receptors. We tested this hypothesis by co-ad-
ministrating QUI, a selective D2/D3 agonist together with HAL 
and examined whether QUI could reverse the effects of HAL. As 
expected, QUI did significantly improve the HAL-induced ma-
ternal behavior deficits. HAL rats pretreated with QUI showed 
shortened pup approach and retrieval latency than those pre-
treated with vehicle. This result is in general agreement with a 
previous study showing that apomorphine, a mixed D1/D2 re-
ceptor agonist with a preferential affinity and potency for the D2 
over D1 receptor subtype (Kebabian and Calne, 1979), reversed 
HAL-induced pup retrieval deficits in postpartum rats (Gior-
dano et al., 1990). We extended this line of research by showing 
that HAL specifically acts on D2 receptors to achieve its disrup-
tive effect. Of note, this finding does not necessarily rule out the 
involvement of the D1 receptor mechanism because HAL does 
have a weak D1 antagonism (Miyamoto et al., 2005), and other 
studies also find that D1 receptors are involved in the regulation 
of maternal behavior (Miller and Lonstein, 2005; Numan et al., 
2005; Numan and Stolzenberg, 2009).
The lack of the effect of DOI treatment on HAL-induced 
maternal behavior deficits is not surprising given the fact that 
DOI is a selective 5-HT2A/2C agonist and HAL lacks an action 
on these serotonergic receptor systems. Interestingly, DOI pre-
treatment further decreased the duration of pup nursing in the 
HAL-treated rats (see Figure 2D). Informal observations indi-
cate that after the pups were returned to the cage, the HAL rats 
pretreated with 2.5 mg/kg of DOI did not approach and retrieve 
their pups, but stayed in the corner of the cage with no appar-
ent movement. This may explain the reduction of pup nurs-
ing by DOI. In light that DOI itself reduces locomotor activity 
(Hameleers et al., 2007; Krebs-Thomson and Geyer, 1996; Mitt-
man and Geyer, 1991; Wing et al., 1990), it is possible that DOI-
induced hypolocomotor activity may have contributed to its 
disruptive effect on pup nursing.
Our original hypothesis that QUI may also attenuate the 
CLZ-induced disruption to some extent, as CLZ also possesses 
a D2 antagonism, was not supported by the present findings. In 
contrast, QUI actually worsened some maternal behavior defi-
cits, such as on pup retrieval and nest building. These findings 
indicate that CLZ-induced maternal deficits are not primarily 
mediated by its weak antagonism of D2 receptor. Our prelimi-
nary work (data not shown) finds that QUI at a dose of 1.0 mg/
kg by itself disrupts pup retrieval and nest building. Therefore, it 
is possible that a combination of clozapine and QUI may provide 
an additive disruption on the CLZ-induced maternal deficits.
The most striking finding from the present study was that 
DOI pretreatment rescued most, if not all, maternal behavior 
deficits induced by CLZ. We found that CLZ rats pretreated with 
DOI took a much shorter time to initiate contact with pups and 
retrieve their pups into the nest sites (Table 2), retrieved more 
pups (Figure 4A) and spent more time licking their pups than 
CLZ rats pretreated with vehicle (Figure 4B). CLZ has a unique 
and multifaceted pharmacological, behavioral and clinical pro-
file in comparison with other antipsychotic drugs (Matsubara et 
al., 1993; Meltzer, 1989; Safferman et al., 1991; Schmauss et al., 
1989) due to its multiple-receptor action, including a relatively 
high affinity for D4, histaminergic (H1), muscarinic, serotoniner-
gic (5-HT2) and alpha-1-adrenergic receptors (Baldessarini et al., 
1992; Lane et al., 1988; Meltzer, 1989; Meltzer et al., 1989a; Miller 
and Hiley, 1974; Seeman, 1992; Zavitsanou et al., 2007), moder-
ate affinity for D1, D2, D5, alpha-2-adrenergic and 5-HT3 recep-
tors (Ellenbroek et al., 1991; Matsubara et al., 1993; Miyamoto et 
al., 2005; Murray and Waddington, 1990; Perry et al., 1983; Rem-
ington and Kapur, 2000). The unique antipsychotic property of 
CLZ (e.g., low EPS and less prolactin elevation) has been corre-
lated with its low affinity and fast dissociation at the D2 recep-
tor (Kapur and Remington, 2001; Kapur and Seeman, 2001; See-
man, 2002). This profile makes it difficult to pinpoint the exact 
mechanisms mediating the antipsychotic and behavioral effects 
of CLZ. Our finding that DOI dose-dependently improved the 
CLZ-induced maternal behavior deficits suggests that CLZ exerts 
its disruptive effect on maternal behavior through a 5-HT2A/2C 
receptor-mediated mechanism, and that this effect thus might 
not be directly related to its antipsychotic efficacy, which is me-
diated by blockade of D2 receptors (Seeman, 2002).
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There are several possible mechanisms underlying the re-
versing effect of DOI on CLZ-induced maternal behavior defi-
cits. First, DOI may directly activate the 5-HT2A/2C receptors lo-
calized in the brain regions important for maternal behavior, 
such as the nucleus accumbens (NA) and the ventral tegmental 
area (VTA), etc. There is considerable evidence demonstrating 
that moderate to high levels of 5-HT2A/2C receptor immunoreac-
tivity (Bubar et al., 2005; Clemett et al., 2000; Cornea-Hébert et 
al., 1999; Jakab and Goldman-Rakic, 1998) and mRNAs (Eberle-
Wang et al., 1997; Pompeiano et al., 1994; Wright et al., 1995) are 
expressed in the NA and VTA, thus, DOI may antagonize CLZ’s 
blockade on 5-HT2A/2C receptors through competitive binding to 
5-HT receptors in these areas to alleviate the CLZ-induced ma-
ternal behavior deficits.
Second, DOI may improve CLZ-induced maternal deficits 
through its indirect action on the dopaminergic systems. The 
mesolimbic dopamine system, originating in the VTA and ter-
minating in the NA has been implicated in the appetitive as-
pects of maternal behavior (Hansen, 1994; Hansen et al., 1991a, 
1991b; Hansen et al., 1993; Numan, 2007; Numan et al., 2005). 
Recently, 5-HT2A/2C receptors were found to be localized on the 
dopamine neurons in the VTA (Bubar and Cunningham, 2007; 
Doherty and Pickel, 2000; Ji et al., 2006; Nocjar et al., 2002). 
This finding provides evidence in support of the possible inter-
action between the serotonin and dopamine systems in the VTA 
(Alex and Pehek, 2007; Di Matteo et al., 2001). More importantly, 
a growing body of evidence shows that 5-HT2 receptors play a 
prominent role in the modulation of mesolimbic dopamine-me-
diated function. For example, in the NA, activation of 5-HT2 re-
ceptor appears to facilitate dopamine release that can be blocked 
by local injection of a 5-HT2 receptor antagonist (Parsons and 
Justice, 1993). DOI, a mixed 5-HT2A/2C agonist, has been shown 
to increase extracellular levels of dopamine in the posterior NA 
(Bowers et al., 2000). Thus, it is possible that DOI may reverse 
the effect of CLZ by regulating the DA release in the NA and thus 
indirectly regulate maternal behavior via the DA system. Future 
research should directly address the neural pathways that medi-
ate the modulatory effects of 5-HT2A/2C receptors on the meso-
limbic dopamine systems.
Third, at the behavioral level, the diminished sedation could 
be a contributing factor in reversing CLZ-induced maternal def-
icits by DOI. In the present study, we noted that DOI treatment 
significantly alleviated CLZ-induced sedative effect as those rats 
showed increased motor activity, no sign of closed eyes or bowed 
head. It has been reported that acute and repeated injection of 
CLZ at a dose of 10.0 mg/kg produces substantial sedation in an-
imals (Chesler and Salamone, 1996). The CLZ-induced sedative 
effect has also been reported in the clinic (Burke and Sebastian, 
1993; Safferman et al., 1991). Moreover, recent work from our lab-
oratory shows that the sedative effect of CLZ contributes to its 
disruption on maternal behavior (Zhao and Li, 2009). At this 
point, it is still premature to suggest that DOI reverses CLZ’s dis-
ruption on maternal behavior by alleviating the sedative effect 
of CLZ, because CLZ is not known to cause sedation by block-
ing 5-HT2A/2C receptors, but rather by blocking alpha-adrener-
gic and histamine receptors (Lieberman et al., 1989; Safferman et 
al., 1991). More research is needed to examine whether CLZ can 
cause sedation via action on 5-HT2A/2C receptors.
Because improvement of CLZ-induced disruption of nest re-
building was not apparently observed after DOI pretreatment, it 
is possible that other neurotransmitter systems may be involved 
in CLZ-induced nest building deficit. One such system could in-
volve the dopamine D2/D3 receptors, as our results show that 
HAL-induced disruption of nest building was reversed and re-
stored to the normal level by QUI, a selective D2/D3 receptor ag-
onist. Other systems may include dopamine D1, D4 and D5 re-
ceptors. CLZ has high affinity for D4 and moderate affinity for 
D1 and D5 receptors. Consistent with this hypothesis, previous 
studies have shown that D1 receptor activity is critical for the reg-
ulation of maternal behavior. Microinjection of a dopamine D1 
receptor antagonist SCH-23390 into the medial preoptic area 
(MPOA) or nucleus accumbens (NA) greatly impairs pup re-
trieval in postpartum rats (Miller and Lonstein, 2005; Numan et 
al., 2005). Microinfusion of a dopamine D1 receptor agonist SKF-
38393 into either the MPOA or the NA promotes the onset of 
maternal behavior in pregnancy-terminated rats (Stolzenberg et 
al., 2007). However, it is unknown whether the D4 and/or D5 re-
ceptors are involved in the regulation of maternal behavior due 
to lack of evidence. Alternatively, nest building activity may still 
be mediated by 5-HT2A/2C receptors, but is more sensitive and 
vulnerable to pharmacological intervention (Li et al., 2004; Silva 
et al., 2001; Zhao and Li, 2009). Future work should address this 
issue in detail.
The present study provides strong evidence supporting the 
involvement of 5-HT2A/2C receptors in the mediation of rat ma-
ternal behavior. Previous work on this issue is inadequate and 
inconsistent. For example, Brunner et al. (1999) reported that 
5-HT1B receptor knockout mother mice did not display pup re-
trieval deficits. More recently, Lerch-Haner et al. (2008) reported 
that transgenic mouse dams with a specific disruption in sero-
tonin neuron development displayed profound maternal deficits 
(e.g., pup retrieval, pup nursing, nest building). This study, how-
ever, did not answer which subtypes of 5-HT receptor are impli-
cated in maternal activity. Other studies have found that 5-HT1B 
and 5-HT2A/2C receptors are involved in maternal aggressive be-
havior (De Almeida et al., 2005, 2006a, 2006b; Olivier et al., 
1995; Veiga et al., 2007). For example, intracerebroventricular in-
jections of DOI, a 5-HT2A/2C agonist, inhibited maternal aggres-
sion in postpartum female rats (De Almeida and Lucion, 1994). 
To the best of our knowledge, the present study was the first to 
demonstrate that 5-HT2A/2C receptors may be important in regu-
lating rat maternal behavior.
Consistent with our previous work (Li et al., 2004), we 
found that HAL and CLZ had different time courses of action. 
HAL tended to produce a prolonged disruption, whereas CLZ 
produced a transient one. For instance, the HAL-induced dis-
ruption of nest building was still apparent even at the 240 min 
test point (4 h post-injection), whereas the effect of CLZ was 
diminished (Figure 1 & Figure 3, C). It appears that the reversal 
effect of QUI on HAL-induced maternal deficits also differed 
in regard to time course of action from that of DOI on CLZ-in-
duced deficits. For example, the reversal effect of DOI on CLZ-
induced disruption of pup retrieval was somewhat delayed in 
onset when compared to that of quinpirole on HAL-induced 
impairment (Figure 1 & Figure 4 A), which may be attributable 
to the rapid peak plasma concentration of quinpirole (Whita-
ker and Lindstrom, 1987).
Taken together, the present study demonstrates an interest-
ing double dissociation receptor mechanism underlying the 
HAL and CLZ-induced maternal behavior deficits. Our data sug-
gest that the HAL-induced maternal deficits are primarily me-
diated by the blockade of D2 dopamine receptors, whereas the 
CLZ-induced maternal deficits are primarily mediated by the 
blockade of 5-HT2A/2C receptors. Because not all components of 
CLZ-induced maternal behavior deficits were reversed by DOI, 
other receptor mechanisms such as the D1 receptor may also be 
involved, prompting the need for further investigation.
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